{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:21:15Z","timestamp":1790936475621,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1016\/j.biomaterials.2009.07.024","type":"journal-article","created":{"date-parts":[[2009,8,3]],"date-time":"2009-08-03T09:34:32Z","timestamp":1249292072000},"page":"6026-6034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide\u2013hyaluronate conjugate for the treatment of corneal neovascularization"],"prefix":"10.1016","volume":"30","author":[{"given":"Eun Ju","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitae","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Sub","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choun-Ki","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei Kwang","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2009.07.024_bib1","doi-asserted-by":"crossref","first-page":"11405","DOI":"10.1073\/pnas.0506112103","article-title":"Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision","volume":"103","author":"Cursiefen","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib2","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature05249","article-title":"Corneal avascularity is due to soluble VEGF receptor-1","volume":"443","author":"Ambati","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1357-2725(01)00023-1","article-title":"Endogenous angiogenesis inhibitors and their therapeutic implications","volume":"33","author":"Cao","year":"2001","journal-title":"Int J Biochem & Cell Biol"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib4","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF00192885","article-title":"Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects","volume":"73","author":"Battegay","year":"1995","journal-title":"J Mol Med"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/01.RES.77.3.638","article-title":"Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells identification of a 5\u2032 enhancer","volume":"77","author":"Liu","year":"1995","journal-title":"Circul Res"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","article-title":"Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy","volume":"26","author":"Zhang","year":"2007","journal-title":"Pro Ret & Eye Res"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib7","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization","volume":"39","author":"Amano","year":"1998","journal-title":"Inv Ophthal & Vis Sci"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1042\/CS20040370","article-title":"The vascular endothelial growth factor (VEGF)\/VEGF receptor system and its role under physiological and pathological conditions","volume":"109","author":"Takahashi","year":"2005","journal-title":"Clin Sci"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1126\/science.1312256","article-title":"The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor","volume":"255","author":"De Vries","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib10","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMe058142","article-title":"Angiogenic pathways in diabetic retinopathy","volume":"353","author":"Aiello","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000098504","article-title":"Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy","volume":"39","author":"Starita","year":"2007","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":"Therapeutic monoclonal antibodies in ophthalmology","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/lrb.2008.6348","article-title":"Corneal (lymph) angiogenesis-from bedside to bench and back: a tribute to Judah Folkman","volume":"6","author":"Regenfuss","year":"2008","journal-title":"Lymph Res & Biol"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib15","first-page":"1207","article-title":"Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis 1","volume":"61","author":"Hiratsuka","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib16","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1158\/1078-0432.CCR-04-1564","article-title":"Anti-Flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis","volume":"11","author":"Bae","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nm731","article-title":"Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1","volume":"8","author":"Luttun","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib18","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/nar\/27.13.2569","article-title":"Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA","volume":"27","author":"Parry","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib19","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1021\/cr941199z","article-title":"Hyaluronan: preparation, structure, properties, and applications","volume":"98","author":"Lapcik","year":"1998","journal-title":"Chem Rev"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1081\/DDC-120002997","article-title":"Penetration enhancers and ocular bioadhesives: two new avenues for ophthalmic drug delivery","volume":"28","author":"Kaur","year":"2002","journal-title":"Drug Dev & Ind Pharm"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/02713688908995755","article-title":"Sodium hyaluronate as an ophthalmic vehicle: some factors governing its effect on the ocular absorption of pilocarpine","volume":"8","author":"Camber","year":"1989","journal-title":"Curr Eye Res (Print)"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0378-5173(89)90193-2","article-title":"Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid","volume":"51","author":"Saettone","year":"1989","journal-title":"Int J Pharm"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00920939","article-title":"Sodium hyaluronate 0.25% used as a vehicle increases the bioavailability of topically administered gentamicin","volume":"231","author":"Bernatchez","year":"1993","journal-title":"Graefe's Arch Clin & Exp Ophthal"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib24","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/10717540590952555","article-title":"Hyaluronan: pharmaceutical characterization and drug delivery","volume":"12","author":"Liao","year":"2005","journal-title":"Drug Deliv"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0021-9258(18)75338-6","article-title":"The polysaccharide of the vitreous humor","volume":"107","author":"Meyer","year":"1934","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib26","series-title":"Practical aspects of hyaluronan based medical products","author":"Kuo","year":"2006"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib27","series-title":"Hyaluronan\u2013cell interactions in morphogenesis","author":"Toole","year":"1998"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.1780300707","article-title":"Hyaluronate inhibition of cell proliferation","volume":"30","author":"Goldberg","year":"1987","journal-title":"Arthritis & Rheumatism"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.matbio.2006.08.261","article-title":"Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways","volume":"26","author":"Slevin","year":"2007","journal-title":"Matrix Biol"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J","article-title":"Early-response gene signalling is induced by angiogenic oligosaccharides of hyaluronan in endothelial cells. Inhibition by non-angiogenic, high-molecular-weight hyaluronan","volume":"71","author":"Deed","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib31","doi-asserted-by":"crossref","first-page":"41046","DOI":"10.1074\/jbc.M109443200","article-title":"Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses","volume":"277","author":"Slevin","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib32","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/1523-1747.ep12396880","article-title":"Application of angiogenic oligosaccharides of hyaluronan increases blood vessel numbers in rat skin","volume":"103","author":"Sattar","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib33","first-page":"249","article-title":"Synergistic effect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro","volume":"75","author":"Montesano","year":"1996","journal-title":"Lab Invest"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib34","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/ijc.2910600511","article-title":"The role of hyaluronan in tumour neovascularization (review)","volume":"60","author":"Rooney","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jconrel.2005.02.012","article-title":"Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles","volume":"104","author":"Kim","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib36","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/jbm.a.30759","article-title":"Selectively crosslinked hyaluronic acid hydrogels for sustained release formulation of erythropoietin","volume":"78","author":"Motokawa","year":"2006","journal-title":"J Biomed Mat Res Part A"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib37","first-page":"3","article-title":"Viscosupplementation: a new concept in the treatment of osteoarthritis","volume":"20","author":"Balazs","year":"1993","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib38","series-title":"Sodium hyaluronate and viscosurgery","author":"Balazs","year":"1983"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib39","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jbm.a.30088","article-title":"Hyaluronic acid grafting mitigates calcification of glutaraldehyde-fixed bovine pericardium","volume":"70","author":"Ohri","year":"2004","journal-title":"J Biomed Mat Res"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib40","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1021\/bc800255y","article-title":"Signal transduction of hyaluronic acid-peptide conjugate for formyl peptide receptor like 1 receptor","volume":"19","author":"Oh","year":"2008","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib41","doi-asserted-by":"crossref","first-page":"13588","DOI":"10.1074\/jbc.275.18.13588","article-title":"Arginine-rich anti-vascular endothelial growth factor peptides inhibit tumor growth and metastasis by blocking angiogenesis","volume":"275","author":"Bae","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib42","series-title":"Bioconjugate techniques","author":"Hermanson","year":"2008"},{"key":"10.1016\/j.biomaterials.2009.07.024_bib43","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1021\/bc015519e","article-title":"Systematic modulation of Michael-type reactivity of thiols through the use of charged amino acids","volume":"12","author":"Lutolf","year":"2001","journal-title":"Bioconjugate Chem"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961209007480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961209007480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T15:11:40Z","timestamp":1758899500000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961209007480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":43,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S0142961209007480"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2009.07.024","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide\u2013hyaluronate conjugate for the treatment of corneal neovascularization","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2009.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}